Form 8-K - Current report:
SEC Accession No. 0001140361-23-001223
Filing Date
2023-01-10
Accepted
2023-01-10 16:30:42
Documents
12
Period of Report
2023-01-09
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K brhc10046500_8k.htm   iXBRL 8-K 24631
  Complete submission text file 0001140361-23-001223.txt   160906

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA erna-20230109.xsd EX-101.SCH 3866
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20230109_lab.xml EX-101.LAB 22547
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20230109_pre.xml EX-101.PRE 16045
6 EXTRACTED XBRL INSTANCE DOCUMENT brhc10046500_8k_htm.xml XML 4233
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 23521480
SIC: 2834 Pharmaceutical Preparations